HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 293/4/R1490    most recent 00329.2007v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lo, C. M. Articles by Tso, P. Search for Related Content PubMed PubMed Citation Articles by Lo, C. M. Articles by Tso, P.

APPETITE, OBESITY, DIGESTION, AND METABOLISM

Interaction of apolipoprotein AIV with cholecystokinin on the control of food intake

Departments of ¹Pathology and Laboratory Medicine and ²Psychiatry, University of Cincinnati, Cincinnati, Ohio; ³Department of Anatomy, Physiology and Cell Biology, School of Veterinary Medicine, University of California, Davis, California; and ⁴Laboratory of Experimental Gerontology, National Institute on Aging, Baltimore, Maryland

Submitted 10 May 2007 ; accepted in final form 17 July 2007

Apolipoprotein AIV (apo AIV) and cholecystokinin (CCK) are peptides that act both peripherally and centrally to reduce food intake by decreasing meal size. The present study examined the effects of intraperitoneally administered bolus doses of recombinant apo AIV, CCK-8, and a combination of subthreshold doses of apo AIV and CCK on 4-h food intake in rats that were fasted overnight. Apo AIV at 100 µg/kg reduced food intake significantly relative to the saline control for 1 h, as did doses of CCK-8 at or above 0.125 µg/kg. Doses of apo AIV (50 µg/kg) or CCK (0.06 µg/kg) alone had no effect on food intake. However, when these subthreshold doses of apo AIV and CCK were administered together, the combination produced a significant inhibition of food intake relative to saline controls (P < 0.001), and the duration of the effect was longer than that caused by the administration of either apo AIV or CCK alone. The satiation effect produced by CCK-8 + apo AIV was attenuated by lorglumide, a CCK1 receptor antagonist. We conclude that, whereas the intraperitoneal administration of doses of either recombinant apo AIV or CCK at or above threshold levels reduces food intake, the coadministration of subthreshold doses of the two peptides is highly satiating and works via CCK1 receptor.

intraperitoneal injection; inhibition; satiation effect